ACELRX PHARMACEUT. DL-01 (R5XA) — Financial Flexibility Index
ACELRX PHARMACEUT. DL-01 (R5XA) has a Financial Flexibility Index of -0.19x as of December 2025. Free cash flow of €-2.44 Million (operating CF €-2.44 Million minus capex €0.00) represents 0% of total liabilities (€12.68 Million). Check ACELRX PHARMACEUT. DL-01 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ACELRX PHARMACEUT. DL-01 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for ACELRX PHARMACEUT. DL-01 across 5 annual periods. For the full cash flow conversion analysis, see ACELRX PHARMACEUT. DL-01 cash flow conversion.
Annual Financial Flexibility Index for ACELRX PHARMACEUT. DL-01 (2021–2025)
Year-by-year free cash flow to debt coverage for ACELRX PHARMACEUT. DL-01. Explore R5XA operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.90x | €-11.36 Million | €-11.36 Million | €12.68 Million | ▲ +27.7% |
| 2024 | -1.24x | €-12.68 Million | €-12.68 Million | €10.23 Million | ▲ +55.2% |
| 2023 | -2.77x | €-17.39 Million | €-17.49 Million | €6.29 Million | ▼ -153.8% |
| 2022 | -1.09x | €-27.97 Million | €-28.33 Million | €25.67 Million | ▼ -339.9% |
| 2021 | -0.25x | €-28.18 Million | €-30.00 Million | €113.79 Million | — |